BCMA CAR-T Yields 100% Response Rate in Small AL Amyloidosis Trial

By News Health
6 hours Ago

(MedPage Today) — As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent American Society of Clinical…

Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsmm/116164

Author :

Publish date : 2025-06-20 15:06:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Blood Tests for Early Cancer; Rethinking Asbestos Ban; Reducing Depression in Cancer

Brief Use of CGM May Enhance Lifestyle Awareness in T2D

FDA OKs Nitisinone for Ultra-Rare Black Urine Disease

GLP-1 Drugs Can Be Used First for Weight Loss, Says American College of Cardiology

Could Israel's bombing trigger a nuclear accident in Iran?

Cancer Concerns Spark Caution Over Weight-Loss Injections